“Genomenon’s AI-driven data has the potential to greatly increase our collective understanding of ENPP1 Deficiency.” – Axel Bolte, Inozyme Pharma

ANN ARBOR, Mich. (PRWEB)
November 11, 2021

Genomenon, Inc.®, an AI-driven genomics company, announced a partnership with Inozyme Pharma to make critical information readily accessible to genetic testing labs and clinicians. This information will help inform diagnosis and thus treatment decisions in patients with ENPP1 Deficiency, a rare disease also known as generalized arterial calcification of infancy (GACI) or autosomal recessive hypophosphatemic rickets Type 2 (ARHR2).

Inozyme Pharma focuses on the development of therapeutics that treat diseases of abnormal mineralization—one of these is ENPP1 Deficiency. ENPP1 Deficiency is a progressive diverse condition with serious manifestations occurring throughout life. Those who present in utero or infancy can experience extensive vascular calcification and neointimal proliferation (overgrowth of smooth muscle cells inside arteries interfering with blood flow). This can result in myocardial infarction, stroke, cardiac failure or multiorgan failure. The condition is lethal in an estimated 50% of affected babies. Children and adults with ENPP1 Deficiency typically experience rickets and osteomalacia (softened bones) and can exhibit a range of signs and symptoms that can include hearing loss, joint and bone pain, arterial calcification, cardiac dysfunction, and neurological complications. There are no approved treatments for ENPP1 Deficiency.

To help inform and accelerate the diagnosis for patients of all ages with this disease, Genomenon produced the world’s most comprehensive variant landscape for ENPP1 Deficiency. This AI-driven and expertly curated genetic dataset, along with information on available clinical trials and therapies, has been made available to doctors, researchers, and clinicians through Genomenon’s Mastermind® Genomic Search Engine.

“Genomenon’s collaboration with Inozyme Pharma represents a shared mission to ensure that no rare disease patient goes undiagnosed or untreated,” said Mike Klein, CEO of Genomenon. “In the rare disease space, knowledge is power—and this effort will put critical information at the fingertips of doctors seeking diagnoses for their patients.”

“Genomenon’s AI-driven data has the potential to greatly increase our collective understanding of ENPP1 Deficiency,” said Axel Bolte, MSc, MBA, Inozyme’s co-founder, president, and CEO. “We expect our collaboration will improve the speed and accuracy of the diagnostic journey for patients with ENPP1 Deficiency by providing the data to them, their caregivers, and medical teams to make informed decisions about their disease, ongoing research, and clinical trials².”

Understanding rare diseases remains a significant challenge for clinicians because actionable information is limited. Many rare diseases have an underlying genetic cause, and treatment plans depend on accurate and timely diagnosis. However, these diagnostic journeys can be complex, exhausting, and time-consuming for patients and their families. In fact, undiagnosed rare disease patients lose an average of 4.8 years¹ of missed intervention opportunities waiting for answers. And once a diagnosis is made, the lack of information on available therapies presents another frustrating scarcity—leaving patients and their caregivers with very few options.

Mastermind is used by more than 1,000 genetic testing laboratories and medical centers across the globe, connecting patient DNA to relevant scientific research in order to make diagnosis and treatment decisions. The data produced by this collaboration will provide a deeper level of information, including whether certain genetic variations are known to be pathogenic for the disease. Most notably, potential treatment options and open drug trials can be easily exported into a clinical report for the treating physician and patient to review.

With its unprecedented AI-driven technology, Genomenon has gained considerable momentum in the genetic variant interpretation space. The Mastermind Genomic Search Engine breaks the “bioinformatics bottleneck” by providing rapid and meaningful genomic information to clinical diagnostic labs and researchers. This latest synergy of critical diagnostic and treatment data is a significant step toward solving the puzzle of rare disease and increasing options for patients.

Genomenon will host a webinar featuring Gus Khursigara, vice president of medical affairs and clinical strategy at Inozyme Pharma on Thursday, November 18 at 11am Eastern. Learn more and register.

About Genomenon

Genomenon is an AI-driven genomics company that organizes the world’s genomic knowledge to connect patient DNA to scientific research in the diagnosis and development of treatments for patients with rare genetic diseases and cancer.

Genomenon was named Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.

For more information, visit Genomenon.com

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY), is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies.

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit Inozyme.com.

_________________________________________

1. Hartin, et al. (2020). Expediting rare disease diagnosis: A call to bridge the gap between clinical and functional genomics. Molecular Medicine, 26(1). https://doi.org/10.1186/s10020-020-00244-5

2. https://clinicaltrials.gov/show/NCT04686175

Share article on social media or email:

The South Jersey MS Center

SCOTCH PLAINS, N.J. (PRWEB)
November 11, 2021

NJ Top Docs has reviewed and approved The South Jersey MS Center for 2021. The neurologists at The South Jersey MS Center include Dr. Steven Bromley, who is also board certified in headache medicine, Dr. Indrani S. Hightower who is ABPN certified, as well as board certified in Clinical Neurophysiology, and Dr. Keith Preis who has ABPN certification as well as expertise in pain management, migraine, and trigger point injections.

In addition to management of Multiple Sclerosis, The South Jersey MS Center team specializes in treating Headaches, Epilepsy, Peripheral Nerve Disorders, Traumatic Brain Injury, Alzheimer’s disease and Parkinson’s disease.

The team at The South Jersey MS Center offers cutting edge biologic immunotherapy infusions, including infusions that treat myasthenia gravis, multiple sclerosis, lupus, amyotrophic lateral sclerosis, and migraine.

In addition, this NJ Top Docs practice is one of the first private infusion suites that will be offering biological infusion therapies for the treatment of Alzheimer’s disease.

To learn more about The South Jersey MS Center, please visit: https://njtopdocs.com/nj-doctors/southjerseymscenter/

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:

“There is still so much we don’t know about MALS. Our journal article is the first to show that there may, in fact, be a neurogenic component to the debilitating syndrome,” says Dr. Shouhed.

BEVERLY HILLS, Calif. (PRWEB)
November 10, 2021

Dr. Daniel Shouhed is as an expert at foregut disease and disorders that involve the upper GI tract. Median arcuate ligament syndrome, or (MALS), is a complicated, uncommon and under-diagnosed disease that often causes chronic pain in the upper part of the abdomen.

Dr. Shouhed contributed his expert knowledge and co-authored the article titled, “Clinico-pathologic findings in patients with median arcuate ligament syndrome (celiac artery compression syndrome)” in the Annals of Diagnostic Pathology – Volume 52, June 2021 edition. Median arcuate ligament syndrome (MALS) is a rare entity characterized by severe post-prandial epigastric pain, nausea, vomiting and/or weight loss. Symptoms have been attributed to vascular compression (celiac artery compression syndrome, CACS), but it remains controversial whether they could be secondary to neural compression. In the study, the clinico-pathologic findings of four MALS patients who underwent robotic or laparoscopic surgery at Cedars Sinai Hospital are described. The findings of this study supported neurogenic compression as a contributing factor in the development of pain and other MALS symptoms and favor the use of MALS rather than CACS as diagnostic terminology. It was determined that to further study the pathogenesis of this unusual syndrome, surgeons should submit all tissues excised during MALS procedures for histopathologic examination.

Link to Article: https://pubmed.ncbi.nlm.nih.gov/33798927/

Clinico-pathologic findings in patients with median arcuate ligament syndrome (celiac artery compression syndrome) – PubMed (nih.gov)

“There is still so much we don’t know about MALS. Our journal article is the first to show that there may, in fact, be a neurogenic component to the debilitating syndrome,” says Dr. Shouhed.

More about Dr. Daniel Shouhed:

Patients suffering from MALS travel from around the globe to have consultations with Dr. Shouhed. With his extensive knowledge and specialized training, Dr. Shouhed is uniquely qualified to offer patients innovative robotic MALS surgery as a possible option for treatment. He has published over 50 peer-reviewed journal articles and chapters in the Journal of JAMA Surgery, JACS and other reputable journals, including several articles specifically on MALS.

Dr. Shouhed has two practice locations in the Los Angeles area, at 2121 Santa Monica Blvd in Santa Monica, CA, (310)-904-6647 and 250 N. Robertson Blvd #106 in Beverly Hills, CA, (310)-890-5834. For more information, please call or visit http://www.drdannyshouhed.com

Share article on social media or email:

Nelson Hardiman was awarded a Tier 1 ranking in Health Care and Administrative/Regulatory Law by the U.S. News & World Report’s “2022 Best Law Firms in America”

Over the course of 2021, the firm has played a central role in the robust healthcare and life sciences transactional climate. With months to go, the combined value of Nelson Hardiman’s transactions this year has already exceeded $2 billion.

LOS ANGELES (PRWEB)
November 10, 2021

Nelson Hardiman received a Tier 1 ranking in Health Care and Administrative/Regulatory Law from U.S. News & World Report in its “2022 Best Law Firms in America” edition. The ranking is just the latest confirmation of Nelson Hardiman’s recognition nationally as one of the elite healthcare and life science law practices in the country. “We love being the lean specialty firm that runs circles around big national practices,” commented firm founder Harry Nelson. “Most clients appreciate our quality more than our competitors’ quantity.”

Over the course of 2021, the firm has played a central role in the robust healthcare and life sciences transactional climate. With months to go, the combined value of Nelson Hardiman’s transactions this year has already exceeded $2 billion. In addition to Nelson Hardiman’s central role in the $400 million merger between 23andMe and Lemonaid Health, Nelson Hardiman also represented teledentistry start-up Byte, a direct-to-consumer provider of clear dental aligners, in its acquisition by Dentsply Sirona valued at over $1 billion. “When Byte needed expertise on regulatory strategy, we turned to Harry Nelson and the team at Nelson Hardiman,” commented Byte co-founder Scott Cohen. “We recommend the firm to anyone trying to innovate in digital health.”

Other noteworthy transactions in 2021 have included regulatory counsel on the public acquisition of the Oncology Institute of Hope and Innovation by DFP Healthcare Acquisitions, Well Health’s acquisition of a majority stake in Wisp, a women’s health telemedicine provider, and LaserAway’s funding from Ares Management’s Private Equity Group. The firm is currently in the midst of significant transactions in behavioral health, as well as cutting-edge psychedelics ventures.

Beyond its pivotal role in the aforementioned transactions, Nelson Hardiman’s regulatory practice has continued to grow steadily in multiple areas of innovation and transformation in U.S. healthcare, from COVID-19 related services such as laboratory services to national pharmacy disrupters to direct-to-consumer genomic testing providers. As in recent years, Nelson Hardiman has maintained what many consider the deepest regulatory practice in the country in behavioral health specialties, including addiction treatment, autism, and other subsectors of mental health treatment. The firm continues to play a leading role in defending government investigations and False Claims Act cases across multiple healthcare sectors.

As the current year winds down, Nelson Hardiman is looking forward to a continued environment of healthcare and life sciences growth driven by innovation in 2022. Among other areas of specialization with multiple ventures already seeking the firm’s advice, Nelson Hardiman is seeing and anticipates even more growth in the number of psychedelics-related, genomic testing, and AI-driven ventures. “As much as our practice addresses the full continuum of healthcare and life science issues, we tend to reflect particular hot spots that are still early in their development.”

About Nelson Hardiman

Nelson Hardiman is the premier healthcare and life sciences firm in Los Angeles, serving healthcare and life science providers, investors, and organizations that need experts on the most difficult questions with deep industry knowledge and relationships. The firm’s litigation practice specializes in defending fraud and abuse and whistleblower actions, government investigations, and other complex business disputes. Nelson Hardiman’s transactional group handles healthcare organization acquisitions, sales, investment, and financings, and Nelson Hardiman’s regulatory team advises on compliance with licensing, operational, and reimbursement issues across the full continuum of healthcare industry sectors, with expertise on Medicare and Medicaid requirements, privacy and data security, FDA, and other regulatory matters. The firm has earned a singular position reputation nationally for its leadership in addressing issues in behavioral health, telehealth, corporate practice of medicine, and emerging therapeutic modalities. More information about the firm is available at http://www.nelsonhardiman.com or at 310.203.2800

Share article on social media or email:

3D Booth Rendering from Ortho Digital Symposium

“It’s a new B2B tool specifically built to help companies in the Ortho industry connect digitally and solve problems together.”

ALTAMONTE SPRINGS, Fla. (PRWEB)
November 10, 2021

http://www.orthodigitalsymposium.com – As the world’s first of its kind business-to-business digital symposium in Orthopedics, ODS is harnessing the momentum of past successes with virtual conventions, to launch a new interactive forum designed to help stakeholders in Orthopedics better execute innovative growth and product development strategies in the new reality.

In the past decade, many believed that the global supply chains and communication channels in the MedTech space were agile and digitally connected. The reality is that the Orthopedic industry has been lacking vital B2B digital connectivity, to ensure scalable and sustainable growth in quickly changing market conditions. The Orthopedic Digital Symposium is solving this problem for:

• 
  Contract Manufacturers
• Medical Device Companies (OEMs) & Inventors
• Consultants: Regulatory Affairs, QMS, Product Development, IP, Sales & Marketing
• Investment Banks & Investors
• Distributors & Agents

“ODS is not meant to replace brick and mortar orthopedic conferences, such as the American Academy of Orthopedic Surgeons or OMTEC,” says Guillaume Viallaneix, ODS Co-Founder and MedTech Momentum President; “It’s a new B2B tool specifically built to help companies in the Ortho industry connect digitally and solve problems together, to everyone’s benefit. It’s about giving organizations the opportunity to network in a single forum, identify partnership opportunities, promote their products or services, increase visibility, unveil innovations, surveil the market and find investors.”

Growth Intelligence shows that hundreds of thousands of businesses around the world have turned to digital solutions during the pandemic to survive and thrive. The business model is working in all industries and is here to stay. It only makes sense for B2B stakeholders in Orthopedics to also benefit from the digital revolution.

As Vivien Poujade, ODS Co-Founder and SYNTHES’3D President, states, “The ODS technology platform is powered by the company’s talented team of software engineers & CG artists. Our goal is to immerse exhibitors and visitors in an interactive virtual environment that easily connects decision-makers in Orthopedics. It is driven by data and focused on solutions in a way that is both productive and entertaining.”

Registration for the February 2-4th, 2022 symposium is now open. Attendees can register for free by clicking here; Exhibitors by clicking here. Spots are limited to only 80 exhibitor spaces for this event.

About ODS The Ortho Digital Symposium (ODS) is produced by MedTech Digital Symposiums, LLC. (MDS), a joint venture between MedTech Momentum, Inc. in the United States, and SYNTHES’3D, SAS. in Europe (France). Created in 2021, MedTech Digital Symposiums leverages the founders decades of MedTech industry experience, virtual networks expertise, and global reach, to address the unmet digital connectivity needs in the MedTech space. ODS is the first symposium to be launched; others are in the works in other specialties.

Share article on social media or email:

GIBLIB, the premier on-demand education and CME-accredited platform for healthcare professionals to learn from the world’s leading medical experts anytime and anywhere

Our goal is to provide healthcare professionals with access to the highest quality education which makes this special mention on TIME’s Best Inventions of 2021 list a milestone and speaks to its goal for a ‘better, smarter, and a bit more fun’ world. — Brian Conyer, CEO and co-founder of GIBLIB

LOS ANGELES (PRWEB)
November 10, 2021

GIBLIB, the premier on-demand education and CME-accredited platform for healthcare professionals to learn from the world’s leading medical experts anytime and anywhere, has been named a special mention on TIME’s Best Inventions of 2021 list. This year’s list places GIBLIB among 49 other movers and shakers across industries like technology, health and wellness, and sustainability looking to improve society and our way of life.

“We are honored to be included in the special mentions category on TIME’s renowned list of 100 budding and established innovators making waves across industries,” said Brian Conyer, CEO and co-founder of GIBLIB. “As an innovator crossing media with healthcare, our goal is to provide healthcare professionals with access to the highest quality education which makes this special mention on TIME’s Best Inventions of 2021 list a milestone and speaks to its goal for a ‘better, smarter, and a bit more fun’ world.”

With many systemic challenges in the healthcare industry exposed by the pandemic, GIBLIB is addressing the industry’s access and equity limitations by delivering high-fidelity, immersive video content from the world’s leading medical professionals and specialists to medical professionals anywhere in the world.

About GIBLIB

GIBLIB is the only streaming media platform to provide medical professionals anywhere in the world access to high-fidelity, immersive video content of the most current medical topics and sought-after surgical procedures performed by the world’s leading specialists. The Company creates, produces and curates high-quality educational videos that feature expert physicians at leading academic medical centers and distributes its content on-demand to medical professionals and students worldwide. GIBLIB produces exclusive content in partnership with leading experts in the medical field, including Mayo Clinic, UCSF Medical Center, Keck Medicine of USC, Cedars Sinai, and Cleveland Clinic.

Share article on social media or email:

“Olansky has a great reputation for focusing on its patients, its provider teams, and community,” Palgon says.

ATLANTA (PRWEB)
November 10, 2021

Olansky Dermatology & Aesthetics – Atlanta’s premier full-service dermatology practice – welcomes board-certified physician assistant Alexandra Palgon to its Buckhead location. The addition of Palgon is another reason patients looking for veteran dermatology providers can choose Olansky.

Palgon has been working in dermatology for nearly 20 years, and she maintains certification with the National Commission on Certification of Physician Assistants. She received her physician assistant certification and Master of Health Sciences degree from Duke University. As a member of both the Georgia Dermatology Physician Assistants organization and the Society of Dermatology Physician Assistants, Palgon stays up to date with the latest in dermatology best practices. She has a special interest in diagnosing early melanomas.

“Olansky has a great reputation for focusing on its patients, its provider teams, and community,” Palgon says. “Its combination of professionalism and compassion aligns with my own values, which makes joining the Olansky team a career highlight.”

Palgon’s seasoned expertise helps bolster and enhance the already strong provider team at the Buckhead location. Patients interested in a full-service dermatology solution in the area can opt for Palgon and her colleagues at Olansky Dermatology & Aesthetics. The members of the practice believe everyone deserves healthy skin. They strive to constantly improve the patient experience, offering medical, surgical, cosmetic, and aesthetic services in a state-of-the-art setting.

To schedule a visit at Olansky Dermatology & Aesthetics’ location in Buckhead (3379 Peachtree Road N.E., Suite 500, Atlanta) call: 404-355-5484.

Olansky Dermatology & Aesthetics is your dermatology solution. Our ability to provide full-service dermatology to patients of all ages is a distinct benefit to choosing our practice. We offer medical, surgical, cosmetic, and aesthetic services to our patients, and even same-day appointments when possible. This makes us not only a convenient solution for your family, but a comprehensive one as well. With services ranging from our in-house Mohs surgery for skin cancer, advanced laser therapy for psoriasis, or our aesthetic services for skin rejuvenation, Olansky Dermatology & Aesthetics can handle all of your skin concerns. For more details, visit our website at OlanskyDermatology.com or call 404-355-5484.

Interviews are available upon request.

Share article on social media or email: